摘要 : Aims: To examine the real-world safety of adding bevacizumab to first-line irinotecan-based chemotherapy for patients with metastatic colorectal cancer (mCRC). Materials and methods: Patients diagnosed with CRC in three Canadian p... 展开
作者 | Beca~ J. M. Dai~ W. F. Pataky~ R. E. Tran~ D. Dvorani~ E. Isaranuwatchai~ W. Peacock~ S. Alvi~ R. Cheung~ W. Y. Earle~ C. C. Gavura~ S. Chan~ K. K. W. |
---|---|
作者单位 | |
期刊名称 | 《Clinical oncology》 |
总页数 | 11 |
语种/中图分类号 | 英语 / R73 |
关键词 | Bevacizumab colorectal cancer observational data real-world evidence retrospective analysis safety OBSERVATIONAL COHORT EFFICACY FOLFIRI FLUOROURACIL LEUCOVORIN OXALIPLATIN IRINOTECAN THERAPY FOLFOX IV |
馆藏号 | N2007EPST0000379 |